06:11 AM EST, 11/06/2025 (MT Newswires) -- Pfizer ( PFE ) said late Wednesday that it will continue to pursue its legal and antitrust claims against Metsera ( MTSR ) after the Delaware Chancery Court denied its request for a temporary restraining order to prevent Metsera ( MTSR ) from terminating its merger agreement in favor of a competing offer from Novo Nordisk ( NVO ) .

Pfizer ( PFE ) said it remains confident in the merits of its case, alleging that Metsera ( MTSR ) and its directors breached their contractual obligations, and that Novo Nordisk's ( NVO ) proposal presents an "illegal scheme" to evade antitrust scrutiny.

The company said it plans to continue litigation in Delaware courts and noted the Federal Trade Commission has recently warned Metsera ( MTSR ) and Novo Nordisk ( NVO ) that proceeding with the transaction could "result in unwinding the deal."

Metsera ( MTSR ) in a separate statement said it was "gratified" by the Delaware court's decision to deny Pfizer's ( PFE ) request.

"Pfizer's ( PFE ) litigation arguments are nonsense. Metsera's ( MTSR ) Board of Directors will continue to stand firm on behalf of shareholders and patients," Metsera ( MTSR ) said.

Shares of Pfizer ( PFE ) were up 0.2% in recent premarket activity, while Metsera ( MTSR ) shares were up 8.4% and Novo Nordisk ( NVO ) was down 1.2%.